PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ulotaront. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

26 hits

Bibliografisk träff 2023-12-19

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.

Yang SM, Ghoshal A, Hubbard JM, Gackière F, Teyssié R, Neale SA, Hopkins SC, Koblan KS, Bristow LJ, Dedic N.

Neuropsychopharmacology · research-article; journal article · DOI 10.1038/s41386-023-01779-x

Bibliografisk träff 2023-10-26

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.

Tsukada H, Chen YL, Xiao G, Lennek L, Milanovic SM, Worden M, Polhamus DG, Chiu YY, Hopkins SC, Galluppi GR.

Clin Pharmacokinet · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s40262-023-01317-4

Bibliografisk träff 2023-09-01

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.

Ågren R, Betari N, Saarinen M, Zeberg H, Svenningsson P, Sahlholm K.

Int J Neuropsychopharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/ijnp/pyad049

Bibliografisk träff 2023-08-07

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.

Perini F, Nazimek JM, Mckie S, Capitão LP, Scaife J, Pal D, Browning M, Dawson GR, Nishikawa H, Campbell U, Hopkins SC, Loebel A, Elliott R, Harmer CJ, Deakin B, Koblan KS.

Schizophrenia (Heidelb) · research-article; journal article · DOI 10.1038/s41537-023-00385-6

Bibliografisk träff 2023-07-13

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.

Kuvarzin SR, Sukhanov I, Onokhin K, Zakharov K, Gainetdinov RR.

Biomedicines · review-article; review; journal article · DOI 10.3390/biomedicines11071977

Bibliografisk träff 2023-05-25

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.

Isaacson SH, Goldstein M, Pahwa R, Singer C, Klos K, Pucci M, Zhang Y, Crandall D, Koblan KS, Navia B, Parkinson's Psychosis TAAR1 Study Group.

Neurol Clin Pract · research-article; journal article · DOI 10.1212/cpj.0000000000200175

Bibliografisk träff 2023-05-10

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.

Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K.

Eur Arch Psychiatry Clin Neurosci · review-article; review; journal article · DOI 10.1007/s00406-023-01580-3

Bibliografisk träff 2023-05-01

Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.

Le GH, Gillissie ES, Rhee TG, Cao B, Alnefeesi Y, Guo Z, Di Vincenzo JD, Jawad MY, March AM, Ramachandra R, Lui LMW, McIntyre RS.

Expert Opin Investig Drugs · systematic review; journal article · DOI 10.1080/13543784.2023.2206559

Bibliografisk träff 2023-04-28

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.

Szabo ST, Hopkins SC, Lew R, Loebel A, Roth T, Koblan KS.

Sleep Med · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.sleep.2023.04.019

Bibliografisk träff 2023-04-01

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP- 363856.

Saarinen M, Mantas I, Flais I, Ågren R, Sahlholm K, Millan MJ, Svenningsson P.

Neuropsychopharmacology · published erratum; correction · DOI 10.1038/s41386-022-01504-0

Bibliografisk träff 2023-03-28

A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.

Tsukada H, Milanovic SM, Darpo B, Xue H, Xiong K, Tripp E, Lennek L, Worden M, Hopkins SC, Galluppi GR.

Clin Transl Sci · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/cts.13512

Bibliografisk träff 2023-03-17

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.

Chen YL, Tsukada H, Milanovic S, Shi L, Li Y, Mao Y, Koblan KS, Galluppi GR.

Neurol Ther · research-article; journal article · DOI 10.1007/s40120-023-00459-8

Bibliografisk träff 2022-12-22

Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.

Højlund M, Correll CU.

Expert Opin Investig Drugs · journal article · DOI 10.1080/13543784.2022.2158811

Bibliografisk träff 2022-11-24

Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.

Feemster JC, Westerland SM, Gossard TR, Steele TA, Timm PC, Jagielski JT, Strainis E, McCarter SJ, Hopkins SC, Koblan KS, St Louis EK.

Sleep Med · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.sleep.2022.11.022

Bibliografisk träff 2022-09-13

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-383856.

Saarinen M, Mantas I, Flais I, Ågren R, Sahlholm K, Millan MJ, Svenningsson P.

Neuropsychopharmacology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41386-022-01421-2

Bibliografisk träff 2022-04-25

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice.

Ren X, Xiong J, Liang L, Chen Y, Zhang G.

Molecules · research-article; journal article · DOI 10.3390/molecules27092755

Bibliografisk träff 2022-04-14

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.

Liang L, Ren X, Xu J, Ma Y, Xue Y, Zhuang T, Zhang G.

Molecules · research-article; journal article · DOI 10.3390/molecules27082550

Bibliografisk träff 2021-12-09

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.

Correll CU, Koblan KS, Hopkins SC, Li Y, Heather Dworak, Goldman R, Loebel A.

NPJ Schizophr · research-article; journal article · DOI 10.1038/s41537-021-00190-z

Bibliografisk träff 2021-12-06

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.

Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, Campbell JE, Dedic N, Hopkins SC, Koblan KS, Xie L.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.1c00527

Bibliografisk träff 2021-10-06

A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study.

Chen YL, Shi Y, LaFayette A, Shi L, Koblan KS, Galluppi GR.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2021.114404

Bibliografisk träff 2021-08-10

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.

Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, Koblan KS.

CPT Pharmacometrics Syst Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/psp4.12692

Bibliografisk träff 2021-08-10

Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs.

Nair PC, Miners JO, McKinnon RA, Langmead CJ, Gregory KJ, Copolov D, Chan SKW, Bastiampillai T.

Mol Psychiatry · research support, non-u.s. gov't; review; journal article · DOI 10.1038/s41380-021-01250-7

Bibliografisk träff 2021-04-20

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans.

Hopkins SC, Dedic N, Koblan KS.

Transl Psychiatry · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1038/s41398-021-01331-9

Bibliografisk träff 2021-04-16

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856.

Begni V, Sanson A, Luoni A, Sensini F, Grayson B, Munni S, Neill JC, Riva MA.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22084119

Bibliografisk träff 2020-04-01

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A.

N Engl J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1911772

Bibliografisk träff 2019-08-01

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action.

Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, Spear KL, Large TH, Campbell UC, Hanania T, Leahy E, Koblan KS.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.119.260281

Go to research.

Publications in the selection

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT<sub>1A</sub> Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.

Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT<sub>1A</sub> receptor agonist SEP- 363856.

A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.

Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.

Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT<sub>1A</sub> receptor agonist SEP-383856.

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice.

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.

A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study.

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.

Binding of SEP-363856 within TAAR1 and the 5HT<sub>1A</sub> receptor: implications for the design of novel antipsychotic drugs.

Effect of TAAR1/5-HT<sub>1A</sub> agonist SEP-363856 on REM sleep in humans.

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856.

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D<sub>2</sub> Receptor Mechanism of Action.